Recruiting

tDCS

Sponsor:

UCLA

Code:

NCT07217223

Conditions

Treatment Resistant Depression (TRD)

Major Depressive Disorder (MDD)

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Spaced Transcranial Direct Current Stimulation (tDCS)

Study Details

Brief summary:

The investigators propose a single-arm, open-label study to evaluate the effectiveness, safety, tolerability and feasibility of at-home transcranial direct current stimulation (tDCS) as a treatment for depression, particularly in cases where patients have not responded well to traditional therapies. Treatment will be delivered over a 2-week period with daily weekday treatments i.e., five tDCS sessions, each lasting 20 minutes, spaced by approximately 20-minute inter-session intervals, for a total of three hours a day. Participants will self-administer treatment at home under direct remote supervision. Pre- and post- treatment neurophysiological biomarkers sessions will also be carried out. The study aims to examine changes in mood, brain activity, and related clinical outcomes before, during, and after treatment, with the goal to provide more information that can be used for future studies.

PLEASE NOTE: THERE WILL BE 4 APPOINTMENTS THAT MUST OCCUR IN PERSON IN SAN DIEGO, CA.

Conditions

Treatment Resistant Depression (TRD)

Major Depressive Disorder (MDD)

Study ID

NCT07217223

Start date

Sep 27, 2025

Status verified date

Aug, 2025

Completion date

Mar, 2027

Anticipated

Primary completion date

Oct 1, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. People between the ages of 18 and 85 at the time of screening.
2. Currently diagnosed with Major Depressive Disorder (MDD) as measured by the MINI and a MADRS score of ≥ 20.
3. Safe for TMS as measures by the TMS Adult Safety Screening (TASS).
4. Medical records confirming a history of failing to achieve clinical response to an adequate antidepressant trial as defined an Antidepressant Treatment History Form (ATHF) score ≥ 3 or ) or shown intolerance to at least two inadequate trials (score 1 or 2), without psychiatric illness due to a general medical condition.
5. Stable internet connection and a device compatible with Microsoft Teams.

Exclusion Criteria:

1. History of psychotic or bipolar disorder or depression with psychotic features;
2. Significant borderline personality disorder;
3. Significant comorbid obsessive-compulsive or post-traumatic stress:
4. Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal;
5. Clinically significant suicidality disorder;
6. Chronic depression (defined as of over 5 years duration);
7. Pregnancy or lactation, lack of adequate birth control in women of childbearing age;
8. History of significant neurologic disease, including dementia, Parkinson's or Huntington's disease, brain tumor, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma with persistent symptoms;
9. Unstable medical illness;
10. Contraindication to receiving tDCS (e.g., ferromagnetic implant, history of seizure, known brain lesion);
11. History of TMS (greater than 15 sessions) without a clinically meaningful response.; History of ketamine (greater than 4 sessions) without a clinically meaningful response;
12. Require a benzodiazepine with a dose > lorazepam 2 mg/day;
13. dermatological conditions contraindicating tDCS;
14. Non-correctable sensory impairments;
15. Inability to consent or participate as an outpatient

Study Design

Enrollment

10 participants

Anticipated

Intervention Model

Single group

Primary purpose

Other

Interventions and Outcome Measures

Arms

experimental: Spaced Transcranial Direct Current Stimulation Treatment

tDCS, a non-invasive neuromodulation technique that applies low-intensity, direct electrical stimulation to the cortex via scalp electrodes, has been extensively researched as a potential treatment for MDD. tDCS enhances neuroplasticity, which is theorized to be responsible for its therapeutic effects and has been presented as a cost-effective solution for MDD. Preclinical evidence supports the potential advantage of spaced stimulation with tDCS to maximally engage neuroplasticity.

tDCS sessions will be self-administered at home under the supervision of a trained clinical research coordinator.

Each treatment day will consist of five tDCS sessions, each lasting 20 minutes, spaced by approximately 20-minute inter-session intervals, for a total of three hours per day.

Other Names:

  • tDCS
  • Soterix Medical miniCT

Interventions

Spaced Transcranial Direct Current Stimulation (tDCS)

tDCS will be self-administered at home under the supervision of a trained clinical research coordinator using the Soterix Medical mini-CT device with remote monitoring via a secure videoconferencing platform (e.g., Microsoft Teams).The device is designed for safe, remote tDCS delivery. Participants will be treated using a stimulation at 2 mA, with a 30-second ramp-up and ramp-down phase.

Primary outcome measure

  • Feasibility (Recruitment) [ Time Frame: From baseline clinical assessment prior to treatment to 12 weeks after last treatment. ]
  • Feasibility (Retention) [ Time Frame: From baseline clinical assessment prior to treatment, to 12 weeks after last treatment. ]
  • Feasibility (Adherence) [ Time Frame: From baseline clinical assessment prior to treatment, to 12 weeks after last treatment. ]
  • Safety of at-home spaced tDCS [ Time Frame: From baseline clinical assessment prior to treatment, to 12 weeks after last treatment. ]
  • Tolerability to spaced tDCS [ Time Frame: From baseline clinical assessment prior to treatment, to 12 weeks after last treatment. ]

Central Contacts and Locations

Central contacts

Interventional Psychiatry

858-966-5832iptrials@health.ucsd.edu

Locations

UCSD Interventional Psychiatry

Recruiting

San Diego, California, United States, 92127

Contacts

UCSD Interventional Psychiatry Clinic

(858)207-0938iptrials@health.ucsd.edu

More Information

Sponsor

University of California, San Diego

Last update posted

Jan 9, 2026

Last verified

Aug, 2025

Keywords

  • Treatment
  • Treatment Resistant Depression
  • Major Depressive Disorder
  • MDD

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, San Diego on 2026-01-09.